Story · Medicine & Biotech · Mind & Brain
Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial
1 outlet · first reported by medRxiv (all subjects) on
Lithium (Li) demonstrates neuroprotective effects relevant to Alzheimer disease (AD). However, its molecular mechanisms remain insufficiently characterized. This study analyzed plasma proteomic profiles from the Li as a Treatment to Prevent Impairment of Cognition in Elders (LATTICE) randomized… (medRxiv (all subjects))
Coverage, in order
-
Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial
Lithium (Li) demonstrates neuroprotective effects relevant to Alzheimer disease (AD). However, its molecular mechanisms remain insufficiently characterized. This study analyzed plasma proteomic profiles from the Li as a Treatment to Prevent Impairment of Cognition in Elders (LATTICE) randomized…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.